Confronto

Eloralintide vs. Semaglutid

Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.

Identità

Categoria

Metabolico

N. CAS

nessun dato

910463-68-2

Peso molecolare

nessun dato

4113.6 g/mol

Emivita

nessun dato

165 h

Sequenza

nessun dato

modifiziertes GLP-1-Analogon (31 AS) mit C18-Fettsäure-Linker

Meccanismo d'azione

Eloralintide

Eloralintide selectively activates amylin receptors (preferentially AMY1R) and promotes satiety. The approach targets weight loss via the amylin axis, complementary to or independent of GLP-1 agents.

Semaglutid

Long-acting agonist at the GLP-1 receptor. Structurally a modified glucagon-like peptide 1 whose long half-life is achieved via a fatty-acid side chain and reversible albumin binding. Acts centrally on satiety and peripherally on glucose-dependent insulin secretion and delayed gastric emptying.

Base di evidenze

Evidenza più alta

RCT sull'uomo

Studi

di cui sull'uomo

Effetti registrati

Contraddizioni aperte

Eventi avversi documentati

Stato legale

Country	Eloralintide	Semaglutid
Svizzera	—	Su prescrizione
Germania	Non approvato	Su prescrizione
Stati Uniti	Non approvato	Su prescrizione

Voci complete

Frequently asked questions

What is the difference between Eloralintide and Semaglutid?: Eloralintide is classified as "Metabolico", while Semaglutid is classified as "Metabolico". Eloralintide: Eloralintide is a selective, long-acting amylin receptor agonist from Eli Lilly for once-weekly subcutaneous use — under investigation for obesity, alone and combined with incretin therapy. Semaglutid: Long-acting GLP-1 receptor agonist. Approved as a medicinal product for type-2 diabetes (Ozempic, Rybelsus), chronic weight management (Wegovy) and cardiovascular risk in obesity. One of the best-studied substances on this platform — many large human RCTs. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Eloralintide or Semaglutid?: The highest available evidence level is "RCT sull'uomo" for Eloralintide and "RCT sull'uomo" for Semaglutid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Eloralintide and Semaglutid in Germany and the United States?: Germania: Eloralintide — Non approvato, Semaglutid — Su prescrizione. Stati Uniti: Eloralintide — Non approvato, Semaglutid — Su prescrizione. These are factual summaries with source and review date on the individual pages.

Country

Eloralintide

Semaglutid

Svizzera

—

Su prescrizione

Germania

Non approvato

Su prescrizione

Stati Uniti

Non approvato

Su prescrizione

Frequently asked questions

What is the difference between Eloralintide and Semaglutid?

Eloralintide is classified as "Metabolico", while Semaglutid is classified as "Metabolico". Eloralintide: Eloralintide is a selective, long-acting amylin receptor agonist from Eli Lilly for once-weekly subcutaneous use — under investigation for obesity, alone and combined with incretin therapy. Semaglutid: Long-acting GLP-1 receptor agonist. Approved as a medicinal product for type-2 diabetes (Ozempic, Rybelsus), chronic weight management (Wegovy) and cardiovascular risk in obesity. One of the best-studied substances on this platform — many large human RCTs. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Eloralintide or Semaglutid?

The highest available evidence level is "RCT sull'uomo" for Eloralintide and "RCT sull'uomo" for Semaglutid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Eloralintide and Semaglutid in Germany and the United States?

Germania: Eloralintide — Non approvato, Semaglutid — Su prescrizione. Stati Uniti: Eloralintide — Non approvato, Semaglutid — Su prescrizione. These are factual summaries with source and review date on the individual pages.